The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.

Published on Aug 9, 2019in Journal of Thrombosis and Haemostasis4.157
· DOI :10.1111/JTH.14594
Magdalena Gierula8
Estimated H-index: 8
(Imperial College London),
Isabelle I. Salles-Crawley6
Estimated H-index: 6
(Imperial College London)
+ 4 AuthorsJosefin Ahnström16
Estimated H-index: 16
(Imperial College London)
BACKGROUND: Activated protein C (APC)-mediated inactivation of factor (F)Va is greatly enhanced by protein S. For inactivation to occur, a trimolecular complex among FVa, APC, and protein S must form on the phospholipid membrane. However, direct demonstration of complex formation has proven elusive. OBJECTIVES: To elucidate the nature of the phospholipid-dependent interactions among APC, protein S, and FVa. METHODS: We evaluated binding of active site blocked APC to phospholipid-coated magnetic beads in the presence and absence of protein S and/or FVa. The importance of protein S and FV residues were evaluated functionally. RESULTS: Activated protein C alone bound weakly to phospholipids. Protein S mildly enhanced APC binding to phospholipid surfaces, whereas FVa did not. However, FVa together with protein S enhanced APC binding (>14-fold), demonstrating formation of an APC/protein S/FVa complex. C4b binding protein-bound protein S failed to enhance APC binding, agreeing with its reduced APC cofactor function. Protein S variants (E36A and D95A) with reduced APC cofactor function exhibited essentially normal augmentation of APC binding to phospholipids, but diminished APC/protein S/FVa complex formation, suggesting involvement in interactions dependent upon FVa. Similarly, FVaNara (W1920R), an APC-resistant FV variant, also did not efficiently incorporate into the trimolecular complex as efficiently as wild-type FVa. FVa inactivation assays suggested that the mutation impairs its affinity for phospholipid membranes and with protein S within the complex. CONCLUSIONS: FVa plays a central role in the formation of its inactivation complex. Furthermore, membrane proximal interactions among FVa, APC, and protein S are essential for its cofactor function.
📖 Papers frequently viewed together
9 Citations
9 Citations
13 Citations
Factor V (FV) is a regulator of both pro- and anticoagulant pathways. It circulates as a single-chain procofactor, which is activated by thrombin or FXa to FVa that serves as cofactor for FXa in prothrombin activation. The cofactor function of FVa is regulated by activated protein C (APC) and protein S. FV can also function as an anticoagulant APC cofactor in the inhibition of FVIIIa in the membrane-bound tenase complex (FIXa/FVIIIa). In recent years, it has become clear that FV also functions i...
24 CitationsSource
#1Salvatore Santamaria (Imperial College London)H-Index: 14
#2Natalia Reglińska-Matveyev (Imperial College London)H-Index: 2
Last. Josefin Ahnström (Imperial College London)H-Index: 16
view all 7 authors...
Abstract Tissue factor pathway inhibitor (TFPI), the main inhibitor of initiation of coagulation, exerts an important anticoagulant role through the factor Xa (FXa)-dependent inhibition of tissue factor/factor VIIa (FVIIa). Protein S is a TFPI cofactor, enhancing the efficiency of FXa inhibition. TFPI can also inhibit prothrombinase assembly by directly interacting with coagulation factor V (FV) which has been activated by FXa. Since full-length TFPI associates with FV in plasma, we hypothesized...
18 CitationsSource
#1Sofia Somajo (Lund University)H-Index: 3
#2Ruzica Livaja Koshiar (Lund University)H-Index: 2
Last. Björn Dahlbäck (Lund University)H-Index: 101
view all 4 authors...
Abstract Introduction Platelets are the main source of microparticles in plasma and the concentration of microparticles is increased in many diseases. As microparticles expose negatively charged phospholipids, they can bind and assemble the procoagulant enzyme-cofactor complexes. Our aim was to elucidate possible regulation of these complexes on microparticles by the anticoagulant protein C system. Materials and methods Platelets were activated with thrombin ± collagen or the calcium ionophore A...
22 CitationsSource
#1Natalia Reglińska-Matveyev (Imperial College London)H-Index: 2
#2Helena M. Andersson (Imperial College London)H-Index: 5
Last. Josefin Ahnström (Imperial College London)H-Index: 16
view all 7 authors...
Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the inhibition of activated factor X (FXa). TFPI Kunitz domain 3 residue Glu226 is essential for enhancement of TFPI by protein S. To investigate the complementary functional interaction site on protein S, we screened 44 protein S point, composite or domain swap variants spanning the whole protein S molecule for their TFPI cofactor function using a thrombin generation assay. Of these variants, two protein S/growth a...
22 CitationsSource
#1Keiji Nogami (Nara Medical University)H-Index: 23
#2Keiko ShinozawaH-Index: 6
Last. Midori Shima (Nara Medical University)H-Index: 41
view all 7 authors...
Factor V (FV) appears to be pivotal in both procoagulant and anticoagulant mechanisms. A novel homozygote (FVNara), a novel mechanism of thrombosis associated with Trp1920→Arg (W1920R), was found in a Japanese boy and was associated with serious deep vein thrombosis despite a low level of plasma FV activity (10 IU/dL). Activated partial thromboplastin time–based clotting assays and thrombin generation assays showed that FVNara was resistant to activated protein C (APC). Reduced susceptibility of...
31 CitationsSource
#1Chunlei Zheng (Cleveland Clinic)H-Index: 3
#1Chunlei Zheng (Cleveland Clinic Lerner Research Institute)H-Index: 1
Last. Bin Zhang (Cleveland Clinic Lerner Research Institute)H-Index: 68
view all 2 authors...
Combined deficiency of factor V (FV) and FVIII (F5F8D) is an autosomal recessive bleeding disorder characterized by simultaneous decreases of both coagulation factors. This review summarizes recent reports on the clinical presentations, treatments, and molecular mechanism of F5F8D. Genetic studies identified LMAN1 and MCFD2 as causative genes for this disorder, revealing a previously unknown intracellular transport pathway shared by the two important blood coagulation factors. LMAN1 and MCFD2 fo...
34 CitationsSource
#1Mary J. HeebH-Index: 33
#2Rolf M. MestersH-Index: 45
Last. John H. GriffinH-Index: 107
view all 6 authors...
Protein S (PS) is an anticoagulant plasma protein whose deficiency is associated with increased risk of venous thrombosis. PS directly inhibits thrombin generation by the blood coagulation pathways by several mechanisms, including by binding coagulation factors (F) Va and Xa. To identify PS sequences that mediate inhibition of FVa activity, antibodies and synthetic peptides based on PS sequence were prepared and employed in plasma coagulation assays, purified component prothrombinase assays, bin...
6 CitationsSource
#1Masahiro Takeyama (UR: University of Rochester)H-Index: 3
#2Hironao WakabayashiH-Index: 21
Last. Philip J. FayH-Index: 64
view all 3 authors...
Although factor (F) VIIIa is inactivated by activated protein C (APC) through cleavages in the FVIII heavy chain-derived A1 (Arg 336) and A2 subunits (Arg 562, the FVIII light chain (LC) contributes to catalysis by binding the enzyme. ELISA-based binding assays showed that FVIII and FVIII LC bound to immobilised active site-modified APC (DEGR-APC) (apparent Kd ~270 nM and 1.0 μM, respectively). Fluid-phase binding studies using fluorescence indicated an estimated Kd of ~590 nM for acrylodan-labe...
5 CitationsSource
#1Thomas J. Cramer (Scripps Research Institute)H-Index: 9
#2Andrew J. Gale (Scripps Research Institute)H-Index: 21
Almost two decades ago an anticoagulant function of factor V (FV) was discovered, as an anticoagulant cofactor for activated protein C (APC). A natural mutant of FV in which the R506 inactivation site was mutated to Gln (FVLeiden) was inactivated slower by APC, but also could not function as anticoagulant cofactor for APC in the inactivation of activated factor VIII (FVIIIa). This mutation is prevalent in populations of Caucasian descent, and increases the chance of thrombotic events in carriers...
27 CitationsSource
#1Josefin Ahnström (Imperial College London)H-Index: 16
#2Helena M. Andersson (Imperial College London)H-Index: 5
Last. David A. Lane (Imperial College London)H-Index: 73
view all 10 authors...
Protein S has an important anticoagulant function by acting as a cofactor for activated protein C (APC). We recently reported that the EGF1 domain residue Asp95 is critical for APC cofactor function. In the present study, we examined whether additional interaction sites within the Gla domain of protein S might contribute to its APC cofactor function. We examined 4 residues, composing the previously reported “Face1” (N33S/P35T/E36A/Y39V) variant, as single point substitutions. Of these protein S ...
28 CitationsSource
Cited By5
#1Josefin Ahnström (Imperial College London)H-Index: 16
#2Gary E. Gilbert (VA Boston Healthcare System)H-Index: 28
#1Elisabetta CastoldiH-Index: 26
#2Nathalie HézardH-Index: 12
Last. Pierre-Emmanuel Morange (AMU: Aix-Marseille University)H-Index: 49
view all 13 authors...
Background Coagulation factor V (FV), present in plasma and platelets, has both pro- and anticoagulant functions. Objective We investigated a FV-deficient patient (FV:C 3%, FV:Ag 4%) paradoxically presenting with recurrent venous thrombosis (11 events) instead of bleeding. Methods/results Thrombophilia screening revealed only heterozygosity for the F2 20210G>A mutation. While thrombin generation in the patient's platelet-poor plasma was suggestive of a hypocoagulable state, thrombin generation i...
#1Masahiro Ieko (HSUH: Health Sciences University of Hokkaido)H-Index: 17
#2Taeko Hotta (Kyushu University)H-Index: 8
Last. Dongchon Kang (Kyushu University)H-Index: 56
view all 12 authors...
Patients with congenital protein S (PS) deficiency show a hereditary predisposition for thrombosis, and PS deficiency is prevalent among Japanese populations. Diagnosis is based on symptoms of thrombosis and reduced PS activity. Three reagents that use different measurement principles for determining PS activity are available in Japan. This study aimed to confirm the possibility of harmonization of these three reagents to establish a universal standard for PS activity in Japanese populations. Co...
#2Josefin Ahnström (Imperial College London)H-Index: 16
Last. Richard A. Marlar (UNM: University of New Mexico)H-Index: 4
view all 5 authors...
Hereditary deficiencies of protein S (PS) increase the risk of thrombosis. However, assessing the plasma levels of PS is complicated by its manifold physiological interactions, while the large inter-individual variability makes it problematic to establish reliable cut-off values. PS has multiple physiological functions, with only two appearing to have significant anticoagulant properties: the activated protein C (APC) and tissue factor pathway inhibitor alpha (TFPIα) cofactor activities. Current...
#1Magdalena Gierula (Imperial College London)H-Index: 8
#2Josefin Ahnström (Imperial College London)H-Index: 16
Protein S is a critical regulator of coagulation that functions as a cofactor for the activated protein C (APC) and tissue factor pathway inhibitor (TFPI) pathways. It also has direct anticoagulant functions, inhibiting the intrinsic tenase and prothrombinase complexes. Through these functions, protein S regulates coagulation during both its initiation and its propagation phases. The importance of protein S in haemostatic regulation is apparent from the strong association between protein S defic...
2 CitationsSource